Text
For Lisa Gulley, early detection is deeply personal.
Screening is not about expecting bad news. It is about reducing uncertainty, and giving you and your clinician more options while there are more options to have.
Lisa Gulley
Advisor
Her father passed away from gastric cancer in 2003. By the time he was diagnosed, the cancer was already terminal. There had been no warning.
Years later, Lisa experienced the uncertainty of a screening pathway herself.
A routine mammogram identified an irregularity. An ultrasound led to a biopsy, followed by four days waiting for the result.
Thankfully, it was benign.
Two very different experiences reinforced the same belief for Lisa. Everyone should have the opportunity to know earlier.
We want to bring forward the experiences that explain why this work matters to the people behind it.
This is Lisa’s.
Originally shared on LinkedIn
Join the conversation and see how others have responded.
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.